Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bomedemstat vs Hydroxyurea in Essential Thrombocythemia
jRCT2031240181Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bomedemstat in thrombocythemia (2 arms), sponsored by Merck & Co. Primary endpoint: Durable clinicohematologic response. Started Jul 2024; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on jRCT2031240181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240181.